1–10 of 13 results for Polypoidal Choroidal Vasculopathy
Intravitreal Aflibercept 8 mg in Patients With Polypoidal Choroidal Vasculopathy Phase 3 PULSAR Trial Subgroup Analysis
David T.W. Wong, MD, FRCS(C), FASRS
Annual Meeting Talks
2023
Expert Panel: Faricimab and Aflibercept 8 mg in AMD
John T. Thompson, MD
Andrew A. Moshfeghi, MD, MBA, FASRS
Manjot K Gill, MD, FASRS
Christina Y Weng, MD, MBA, FASRS
Ferhina S Ali, MD, MPH
Ian Pearce, MB ChB BSc FRCOPHTH
2024
Submacular Hemorrhage PCV
Shobhit Chawla, M.S.
Retina Image Bank: Images of the Week
2022
Choroidal Disturbance in Polypoidal Choroidal Vasculopathy: Insights From Dynamic Indocyanine Green Angiography
Gemmy Chui Ming Cheung, FRCOphth
Updates from the Field
Episcleral Brachytherapy for Exudative Macular Degeneration
Gregg T. Kokame, MD, MMM, FASRS
On Demand Cases, Courses, and Papers
2020
Branching vascular network..Polypoidal choroidal vasculopathy
Surgical Case Conference Aleksandra Rachitskaya
Aleksandra V. Rachitskaya, MD, FASRS
2019
EVEREST II Study: Evaluation of Indocyanine Green Angiographic Features in Symptomatic Macular Polypoidal Choroidal Vasculopathy Over 24 Months
Colin S Tan, MBBS, MMed (Ophth), FRCSEd (Ophth)
Identifying Features on Fundus Photos, OCT, or Fluorescein Angiography to Diagnose Polypoidal Choroidal Vasculopathy Without ICG Angiography
Jun Kong, MD, PhD